ALLR
Allarity Therapeutics, Inc.
Price Chart
Latest Quote
$1.61
-0.09 (-5.29%)
Current Price
| Previous Close | $1.70 |
| Open | $1.71 |
| Day High | $1.72 |
| Day Low | $1.56 |
| Volume | 156,949 |
Stock Information
| Shares Outstanding | 15.91M |
| Total Debt | $1.40M |
| Cash Equivalents | $14.77M |
| Revenue | $320K |
| Net Income | $-11.23M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $25.62M |
| EPS (TTM) | $-0.70 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.99M |
| Sales | $320K |
| Income | $-11.23M |
| Book/sh | $0.52 |
| Cash/sh | $0.93 |
| Employees | 7 |
Financial Ratios
| Quick Ratio | 1.86 |
| Current Ratio | 2.13 |
| Debt/Eq | 14.24 |
Returns & Margins
| ROA | -38.52% |
| ROE | -103.80% |
| Gross Margin | 100.00% |
| Operating Margin | -911.88% |
Ownership
| Insider Ownership | 4.85% |
| Institutional Ownership | 6.15% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.66 |
| P/S | 80.05 |
| P/B | 3.12 |
Analyst Data
| Recommendation | none |
| Target Price | $9.75 |
Technical Indicators
| SMA20 | $1.60 |
| SMA50 | $1.40 |
| SMA200 | $1.29 |
| RSI | 62.15 |
| ATR | 0.1668 |
| Shares Float | 15.74M |
| Short Float | 1.78% |
| Short Ratio | 2.16 |
| Volatility | 0.38 |
| Rel Volume | 0.59 |
Performance History
| Week | -1.83% |
| Month | +8.78% |
| Quarter | +29.84% |
| 6 Months | +47.71% |
| YTD | +41.23% |
| Year | +85.06% |
| 3 Years | -99.97% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $1.61 | 157,000 |
| 2026-06-04 | $1.70 | 213,700 |
| 2026-06-03 | $1.58 | 134,300 |
| 2026-06-02 | $1.69 | 167,100 |
| 2026-06-01 | $1.72 | 314,800 |
| 2026-05-29 | $1.64 | 214,200 |
| 2026-05-28 | $1.67 | 228,800 |
| 2026-05-27 | $1.73 | 505,100 |
| 2026-05-26 | $1.68 | 317,700 |
| 2026-05-22 | $1.77 | 316,500 |
| 2026-05-21 | $1.66 | 572,200 |
| 2026-05-20 | $1.49 | 135,900 |
| 2026-05-19 | $1.49 | 193,900 |
| 2026-05-18 | $1.43 | 158,200 |
| 2026-05-15 | $1.35 | 265,400 |
| 2026-05-14 | $1.51 | 178,400 |
| 2026-05-13 | $1.54 | 100,900 |
| 2026-05-12 | $1.52 | 368,800 |
| 2026-05-11 | $1.68 | 411,900 |
| 2026-05-08 | $1.55 | 355,300 |
| 2026-05-07 | $1.50 | 276,600 |
| 2026-05-06 | $1.48 | 560,300 |
About Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
đ° Latest News
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Zacks âĸ 2026-06-03T13:40:06Z
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Zacks âĸ 2026-05-18T13:40:03Z
Allarity closes $20M financing for stenoparib advancement
TipRanks âĸ 2026-03-07T13:19:41Z
Allarity CEO says 2026 represents an âinflection pointâ
TipRanks âĸ 2026-01-01T13:05:34Z
Sector Update: Health Care Stocks Higher Late Afternoon
MT Newswires âĸ 2025-08-26T19:51:03ZBC-Most Active Stocks
Associated Press Finance âĸ 2025-08-26T14:30:17Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $320,000 | $0 | $0 | $0 |
| Operating Revenue | $320,000 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $185,000 | $653,000 | $498,000 | $223,000 |
| Total Expenses | $12,925,000 | $17,538,000 | $17,129,000 | $16,892,000 |
| Other Income Expense | $758,000 | $-7,238,000 | $5,787,000 | $-494,000 |
| Net Non Operating Interest Income Expense | $616,000 | $-120,000 | $-476,000 | $-193,000 |
| Interest Expense Non Operating | $185,000 | $653,000 | $498,000 | $223,000 |
| Operating Expense | $12,925,000 | $17,538,000 | $17,129,000 | $16,892,000 |
| General And Administrative Expense | $6,324,000 | $11,442,000 | $10,026,000 | $9,962,000 |
| Other Non Operating Income Expenses | - | - | $-591,000 | - |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,231,000 | $-24,515,000 | $-11,901,000 | $-16,058,000 |
| Net Interest Income | $616,000 | $-120,000 | $-476,000 | $-193,000 |
| Interest Income | $801,000 | $533,000 | $22,000 | $30,000 |
| Normalized Income | $-11,989,000 | $-17,387,768 | $-16,939,620 | $-15,606,743 |
| Net Income From Continuing And Discontinued Operation | $-11,231,000 | $-24,515,000 | $-11,901,000 | $-16,058,000 |
| Total Operating Income As Reported | $-12,605,000 | $-27,241,000 | $-17,129,000 | $-34,463,000 |
| Net Income Common Stockholders | $-11,231,000 | $-25,154,000 | $-20,416,000 | $-21,051,000 |
| Net Income | $-11,231,000 | $-24,515,000 | $-11,901,000 | $-16,058,000 |
| Net Income Including Noncontrolling Interests | $-11,231,000 | $-24,515,000 | $-11,901,000 | $-16,058,000 |
| Net Income Continuous Operations | $-11,231,000 | $-24,515,000 | $-11,901,000 | $-16,058,000 |
| Pretax Income | $-11,231,000 | $-24,896,000 | $-11,818,000 | $-17,579,000 |
| Special Income Charges | $0 | $-9,703,000 | $0 | $-16,591,000 |
| Interest Income Non Operating | $801,000 | $533,000 | $22,000 | $30,000 |
| Operating Income | $-12,605,000 | $-17,538,000 | $-17,129,000 | $-16,892,000 |
| Per Share | ||||
| Diluted EPS | - | $-15.65 | $-6031.31 | $-31799.09 |
| Basic EPS | - | $-15.65 | $-6031.31 | $-31799.09 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-110,768 | $1,339,380 | $-42,743 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,804,000 | $-16,996,000 | $-17,661,000 | $-16,802,000 |
| Total Unusual Items | $758,000 | $-7,238,000 | $6,378,000 | $-494,000 |
| Total Unusual Items Excluding Goodwill | $758,000 | $-7,238,000 | $6,378,000 | $-494,000 |
| Reconciled Depreciation | $-13,000 | $9,000 | $37,000 | $60,000 |
| EBITDA (Bullshit earnings) | $-11,046,000 | $-24,234,000 | $-11,283,000 | $-17,296,000 |
| EBIT | $-11,046,000 | $-24,243,000 | $-11,320,000 | $-17,356,000 |
| Diluted NI Availto Com Stockholders | $-11,231,000 | $-25,154,000 | $-20,416,000 | $-21,051,000 |
| Tax Provision | $0 | $-381,000 | $83,000 | $-1,521,000 |
| Impairment Of Capital Assets | $0 | $9,703,000 | $0 | $17,571,000 |
| Gain On Sale Of Security | $758,000 | $2,465,000 | $6,378,000 | $16,097,000 |
| Research And Development | $6,601,000 | $6,096,000 | $7,103,000 | $6,930,000 |
| Selling General And Administration | $6,324,000 | $11,442,000 | $10,026,000 | $9,962,000 |
| Other Gand A | $6,324,000 | $11,442,000 | $10,026,000 | $9,962,000 |
| Diluted Average Shares | - | $1,606,989 | $3,385 | $662 |
| Basic Average Shares | - | $1,606,989 | $3,385 | $662 |
| Preferred Stock Dividends | - | $639,000 | $8,515,000 | $4,993,000 |
| Gain On Sale Of Ppe | - | - | $0 | $1,780,000 |
| Other Special Charges | - | - | - | $800,000 |
| Minority Interests | - | - | - | - |
Fetched: 2026-06-01
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $9,828,000 | $11,811,000 | $-12,622,000 | $-7,659,000 |
| Total Assets | $18,258,000 | $22,650,000 | $11,862,000 | $14,544,000 |
| Total Non Current Assets | $330,000 | $309,000 | $9,891,000 | $9,576,000 |
| Current Assets | $17,928,000 | $22,341,000 | $1,971,000 | $4,968,000 |
| Prepaid Assets | $2,346,000 | $579,000 | $859,000 | $727,000 |
| Receivables | $895,000 | $2,229,000 | $946,000 | $871,000 |
| Taxes Receivable | $895,000 | $813,000 | $946,000 | $871,000 |
| Accounts Receivable | $0 | $1,416,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $14,687,000 | $19,533,000 | $166,000 | $2,029,000 |
| Cash And Cash Equivalents | $14,687,000 | $19,533,000 | $166,000 | $2,029,000 |
| Cash Financial | $14,687,000 | $19,533,000 | $166,000 | $2,029,000 |
| Goodwill And Other Intangible Assets | - | $0 | $9,871,000 | $9,549,000 |
| Other Intangible Assets | - | - | $9,871,000 | $9,549,000 |
| Current Deferred Assets | - | - | $0 | $1,341,000 |
| Investmentin Financial Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $1,400,000 | $1,350,000 | $1,300,000 | $3,735,000 |
| Current Debt And Capital Lease Obligation | $1,400,000 | $1,350,000 | $1,300,000 | $2,652,000 |
| Current Debt | $1,400,000 | $1,350,000 | $1,300,000 | $2,644,000 |
| Other Current Borrowings | $1,400,000 | $1,350,000 | $1,300,000 | $2,644,000 |
| Net Debt | - | - | $1,134,000 | $1,698,000 |
| Long Term Debt And Capital Lease Obligation | - | - | - | $1,083,000 |
| Long Term Debt | - | - | - | $1,083,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,430,000 | $10,839,000 | $14,613,000 | $12,654,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $446,000 | $1,432,000 |
| Current Liabilities | $8,430,000 | $10,839,000 | $14,167,000 | $11,222,000 |
| Payables And Accrued Expenses | $7,030,000 | $9,488,000 | $9,784,000 | $8,196,000 |
| Interest Payable | $461,000 | $281,000 | $101,000 | $0 |
| Payables | $4,363,000 | $4,256,000 | $8,475,000 | $6,292,000 |
| Total Tax Payable | $81,000 | $74,000 | $59,000 | $41,000 |
| Income Tax Payable | $81,000 | $74,000 | $59,000 | $41,000 |
| Accounts Payable | $4,282,000 | $4,182,000 | $8,416,000 | $6,251,000 |
| Non Current Deferred Liabilities | - | $0 | $446,000 | $349,000 |
| Non Current Deferred Taxes Liabilities | - | $0 | $446,000 | $349,000 |
| Other Current Liabilities | - | $1,000 | $3,083,000 | $374,000 |
| Current Notes Payable | - | - | $0 | $2,644,000 |
| Derivative Product Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $9,828,000 | $11,811,000 | $-4,493,000 | $-113,000 |
| Total Equity Gross Minority Interest | $9,828,000 | $11,811,000 | $-2,751,000 | $1,890,000 |
| Stockholders Equity | $9,828,000 | $11,811,000 | $-2,751,000 | $1,890,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,021,000 | $-354,000 | $-411,000 | $-721,000 |
| Other Equity Adjustments | $-1,021,000 | $-354,000 | $-411,000 | $-721,000 |
| Retained Earnings | $-130,197,000 | $-118,966,000 | $-94,451,000 | $-82,550,000 |
| Preferred Stock Equity | - | - | $1,742,000 | $2,003,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $0 |
| Other | ||||
| Treasury Shares Number | $2,949,639 | - | $0 | - |
| Ordinary Shares Number | $16,080,980 | $7,302,797 | $9,811 | $662 |
| Share Issued | $19,030,619 | $7,302,797 | $9,811 | $662 |
| Tangible Book Value | $9,828,000 | $11,811,000 | $-14,364,000 | $-9,662,000 |
| Invested Capital | $11,228,000 | $13,161,000 | $-3,193,000 | $3,614,000 |
| Working Capital | $9,498,000 | $11,502,000 | $-12,196,000 | $-6,254,000 |
| Total Capitalization | $9,828,000 | $11,811,000 | $-2,751,000 | $2,973,000 |
| Treasury Stock | $3,190,000 | $0 | - | - |
| Additional Paid In Capital | $144,233,000 | $131,130,000 | $90,369,000 | $83,158,000 |
| Capital Stock | $3,000 | $1,000 | $1,742,000 | $2,003,000 |
| Common Stock | $3,000 | $1,000 | $0 | $0 |
| Current Accrued Expenses | $2,667,000 | $5,232,000 | $1,309,000 | $1,904,000 |
| Net PPE | $330,000 | $309,000 | $20,000 | $27,000 |
| Gross PPE | $330,000 | $309,000 | $20,000 | $27,000 |
| Other Properties | $330,000 | $309,000 | $20,000 | $27,000 |
| Preferred Stock | - | $0 | $1,742,000 | $2,003,000 |
| Capital Lease Obligations | - | - | $0 | $8,000 |
| Current Capital Lease Obligation | - | - | $0 | $8,000 |
| Long Term Capital Lease Obligation | - | - | - | $0 |
| Other Short Term Investments | - | - | - | $0 |
| Line Of Credit | - | - | - | - |
| Investments And Advances | - | - | - | - |
| Available For Sale Securities | - | - | - | - |
| Accumulated Depreciation | - | - | - | - |
Fetched: 2026-06-01
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-14,828,000 | $-17,650,000 | $-12,745,000 | $-16,835,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-14,820,000 | $-17,352,000 | $-12,745,000 | $-16,817,000 |
| Cash Flow From Continuing Operating Activities | $-14,820,000 | $-17,352,000 | $-12,745,000 | $-16,817,000 |
| Operating Gains Losses | $1,237,000 | $-2,803,000 | $-5,833,000 | $-18,340,000 |
| Investing Activities | ||||
| Capital Expenditure | $-8,000 | $-298,000 | - | $-18,000 |
| Investing Cash Flow | $-8,000 | $-298,000 | $0 | $791,000 |
| Cash Flow From Continuing Investing Activities | $-8,000 | $-298,000 | $0 | $791,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-3,190,000 | $-3,500,000 | $-6,654,000 | $-1,511,000 |
| Issuance Of Capital Stock | $13,838,000 | $40,292,000 | $18,055,000 | $0 |
| Financing Cash Flow | $10,648,000 | $36,792,000 | $10,995,000 | $-1,311,000 |
| Cash Flow From Continuing Financing Activities | $10,648,000 | $36,792,000 | $10,995,000 | $-1,311,000 |
| Net Preferred Stock Issuance | $0 | $-562,000 | $-5,494,000 | $-1,511,000 |
| Preferred Stock Issuance | $0 | $2,938,000 | $1,160,000 | $0 |
| Net Common Stock Issuance | $10,648,000 | $37,354,000 | $16,895,000 | $0 |
| Common Stock Issuance | $13,838,000 | $37,354,000 | $16,895,000 | $0 |
| Net Other Financing Charges | - | - | - | $-800,000 |
| Other | ||||
| Repayment Of Debt | $0 | $-1,340,000 | $-3,699,000 | $0 |
| Issuance Of Debt | $0 | $1,340,000 | $1,050,000 | $1,000,000 |
| End Cash Position | $14,687,000 | $19,533,000 | $166,000 | $2,029,000 |
| Beginning Cash Position | $19,533,000 | $166,000 | $2,029,000 | $19,555,000 |
| Effect Of Exchange Rate Changes | $-667,000 | $225,000 | $-113,000 | $-189,000 |
| Changes In Cash | $-4,179,000 | $19,142,000 | $-1,750,000 | $-17,337,000 |
| Preferred Stock Payments | $0 | $-3,500,000 | $-6,654,000 | $-1,511,000 |
| Common Stock Payments | $-3,190,000 | $0 | - | - |
| Net Issuance Payments Of Debt | $0 | $0 | $-2,649,000 | $1,000,000 |
| Net Long Term Debt Issuance | $0 | $0 | $-2,649,000 | $1,000,000 |
| Long Term Debt Payments | $0 | $-1,340,000 | $-3,699,000 | $0 |
| Long Term Debt Issuance | $0 | $1,340,000 | $1,050,000 | $1,000,000 |
| Net PPE Purchase And Sale | $-8,000 | $-298,000 | $0 | $-18,000 |
| Purchase Of PPE | $-8,000 | $-298,000 | $0 | $-18,000 |
| Change In Working Capital | $-5,680,000 | $63,000 | $3,352,000 | $-328,000 |
| Change In Other Current Assets | $-150,000 | $94,000 | $1,350,000 | $-1,077,000 |
| Change In Payables And Accrued Expense | $-3,831,000 | $-557,000 | $2,226,000 | $1,466,000 |
| Change In Accrued Expense | $-2,699,000 | $3,536,000 | $43,000 | $-4,722,000 |
| Change In Payable | $-1,132,000 | $-4,093,000 | $2,183,000 | $6,188,000 |
| Change In Account Payable | $-1,139,000 | $-4,108,000 | $2,165,000 | $6,207,000 |
| Change In Tax Payable | $7,000 | $15,000 | $18,000 | $-19,000 |
| Change In Income Tax Payable | $7,000 | $15,000 | $18,000 | $-19,000 |
| Change In Prepaid Assets | $-1,603,000 | $274,000 | $-190,000 | $-618,000 |
| Change In Receivables | $-96,000 | $45,000 | $-26,000 | $0 |
| Other Non Cash Items | $385,000 | $566,000 | $1,574,000 | $138,000 |
| Stock Based Compensation | $482,000 | $71,000 | $-71,000 | $1,752,000 |
| Asset Impairment Charge | $0 | $9,703,000 | $0 | $17,571,000 |
| Deferred Tax | $0 | $-446,000 | $97,000 | $-1,612,000 |
| Deferred Income Tax | $0 | $-446,000 | $97,000 | $-1,612,000 |
| Depreciation Amortization Depletion | $-13,000 | $9,000 | $37,000 | $60,000 |
| Depreciation And Amortization | $-13,000 | $9,000 | $37,000 | $60,000 |
| Gain Loss On Investment Securities | $-1,000 | $-2,677,000 | $-5,654,000 | $-17,010,000 |
| Net Foreign Currency Exchange Gain Loss | $1,238,000 | $-126,000 | $-179,000 | $450,000 |
| Net Income From Continuing Operations | $-11,231,000 | $-24,515,000 | $-11,901,000 | $-16,058,000 |
| Proceeds From Stock Option Exercised | - | $0 | $2,243,000 | $0 |
| Change In Other Working Capital | - | $207,000 | - | - |
| Change In Other Current Liabilities | - | $0 | $-8,000 | $-99,000 |
| Interest Paid Supplemental Data | - | - | $34,000 | $85,000 |
| Income Tax Paid Supplemental Data | - | - | $6,000 | $12,000 |
| Net Intangibles Purchase And Sale | - | - | $0 | $809,000 |
| Sale Of Intangibles | - | - | $0 | $809,000 |
| Gain Loss On Sale Of PPE | - | - | $0 | $-1,780,000 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Changes In Account Receivables | - | - | - | - |
Fetched: 2026-06-01